Key Stats for IBRX Stock
- Price Change for IBRX stock: +41.86%
- IBRX Share Price as of Feb. 18: $8.54
- 52-Week High: $8.68
- IBRX Stock Price Target: $11.80
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
ImmunityBio (IBRX) stock jumped 40% after a wave of regulatory and clinical updates highlighted the commercial potential of its lead immunotherapy, Anktiva.
European regulators granted conditional marketing authorization for Anktiva in combination with BCG to treat certain patients with BCG‑unresponsive non‑muscle invasive bladder cancer, expanding the drug’s reach beyond the United States.
Reuters also reported updated Phase 2 data in glioblastoma and new Phase 2 trials for CAR‑NK cell therapy programs, reinforcing the breadth of the company’s pipeline.
At the same time, the company has been steadily announcing geographic expansion moves, including a new Saudi subsidiary to drive growth in the Middle East and North Africa, which investors see as an important long‑term growth channel.
Those milestones arrive on top of earlier approvals that helped transform ImmunityBio into a commercial‑stage biotech. In the United States, Anktiva already holds FDA approval, in combination with BCG, for adult patients with BCG‑unresponsive non‑muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors.
Together, these regulatory wins help explain why TIKR shows IBRX’s one‑year total return above 150% and why trading volume has surged, with average three‑month volume over 27 million shares.
See analysts’ growth forecasts and price targets for IBRX stock (It’s free!) >>>
What the Market Is Telling Us About IBRX Stock
Even after the latest spike, ImmunityBio’s share price of about $9 still sits below the Street’s roughly $11.80 average target, with individual analyst estimates ranging from the mid‑single digits up to $24.
The stock has also swung from a 52‑week low near $1.83 to a recent high of $8.68, underscoring how quickly sentiment can change in response to clinical and regulatory news.
Financial statements from TIKR highlight both the opportunity and the risk. Over the last twelve months, ImmunityBio generated about $82.6 million of revenue versus only $0.93 million three years earlier, representing extremely rapid growth from a small base.
However, operating losses exceeded $260 million over the same period, net losses were more than $340 million, and free cash flow was roughly negative $325 million, reflecting substantial investment in trials and launches.
The balance sheet shows total assets of around $519 million but total liabilities of over $1.0 billion, including more than $800 million of long‑term debt and capital leases, so the company remains reliant on external financing and equity issuance to fund operations.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does IBRX Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
